Can You Take FOXO4-DRI With Tirzepatide or Semaglutide?

Every figure is an all-in monthly price covering medication, physician review, refill management and shipping, with no separate membership fee. Pepti is cash-pay and does not bill insurance. FOXO4-DRI is a vial only: there is no Pen version and it is not part of any Pepti blend.

• No study has tested the combination. There is no human trial of FOXO4-DRI at all, so there is certainly none alongside a GLP-1.
• No interaction has been described. That is an absence of data, not evidence of safety. It is why a physician reviews every medication you take rather than a form.
• FOXO4-DRI is injected, so gastric emptying is not the issue. GLP-1 medications slow gastric emptying, which can change how oral medications are absorbed. That does not apply to a subcutaneous injection.
• The goals do not overlap. Nothing in the FOXO4-DRI research measured body weight, appetite or glucose, and no one should expect it to add to a GLP-1's effect.

The two have distinct side-effect pictures, which helps if something new appears.

For swelling of the face, lips or throat, widespread hives, trouble breathing, faintness or chest pain, call 911 first. If you think you injected far more than your directions, call Poison Control at 1-800-222-1222 and message your care team. Alongside a weekly GLP-1 injection, FOXO4-DRI means six injections a week, so rotating between abdomen and thigh matters. Technique is in how to inject peptides safely, and the full GLP-1 list is in GLP-1 side effects.

These are about FOXO4-DRI itself rather than the pairing, but anyone adding it to a GLP-1 plan should know them.

Put all of it on your intake. Neither point is a reason to stop a GLP-1 you are already taking; it is information your physician needs before adding FOXO4-DRI.

Everything above applies to semaglutide, which acts at one incretin receptor where tirzepatide acts at two. FOXO4-DRI has no mechanism that overlaps with either. Semaglutide and tirzepatide are never taken together. The full comparison is in semaglutide vs tirzepatide, and the wider pairing picture is in what peptides can you take with tirzepatide.

1. Name the goal. FOXO4-DRI is an experimental senolytic, not a weight or energy medication. If what you want is help with weight, the GLP-1 is the medication with the evidence. If you want an anti-aging option with human data, your physician may suggest something else first; see NAD+ vs FOXO4-DRI.
2. List everything at intake, including cancer history, lung disease and every medication and supplement.
3. Start one thing at a time, away from a GLP-1 dose step, so any change has one plausible cause.
4. Follow each label separately. At Pepti's typical directions, FOXO4-DRI is 0.25 mL (25 units) under the skin once daily Monday through Friday, 0.5 mg per dose from the 2 mg/mL vial, 20 doses per vial, about four weeks. Tirzepatide and semaglutide are once weekly. Never mix vials in one syringe.
5. Report what happened, including nothing. There is no described acute effect of FOXO4-DRI, so noticing nothing during a vial is consistent with the mechanism.

Your physician sets your directions after reviewing your intake, and every vial arrives with its directions printed on the label. The unit chart is in FOXO4-DRI dosage, and the general principles of combining are in can you take two peptides together.

Tirzepatide and semaglutide have a very large human evidence base in their branded forms. FOXO4-DRI has none: one foundational mouse paper in Cell in 2017, a 2025 structural study in Nature Communications, a handful of mouse and cell studies in specific tissues, and two studies of human cells outside the body. No dose-finding, pharmacokinetic or safety study in people has been published. The research is set out benefit by benefit in FOXO4-DRI benefits.

The accurate statement is narrow: two medications on unrelated targets, no described interaction, distinct side-effect pictures, and no study of the pairing. Anyone presenting FOXO4-DRI as a GLP-1 add-on with a measured benefit is describing something that has not been tested.

Compounded medications are not FDA approved. FOXO4-DRI does not appear in Category 1, 2 or 3 of the FDA's 503A nominated-substances document updated 14 May 2026, is not on the FDA's significant-safety-risk page, and has not been on an advisory committee agenda; the FDA has not evaluated it either way. Compounded tirzepatide and semaglutide are the same active ingredients as the branded products, and the trial data belongs to the manufactured products. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.

1. Complete a free online intake covering your history, medications, allergies and what you want help with.
2. A physician licensed in your state reviews it, usually within 24 hours.
3. If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares each prescription. Lot test results are published at /quality/lab-results.
4. Each vial ships refrigerated with ice packs, with sterile syringes and alcohol prep pads, and its directions printed on the vial.
5. Refills run every 28 days, one vial per fill, and your care team stays reachable for questions and side effects.

Pepti prescribes in most US states, not currently in Oklahoma, and the assessment confirms availability for your state. Step by step: how to get FOXO4-DRI prescribed online, how to get tirzepatide prescribed online and how to get semaglutide prescribed online.